MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.97 -1.49

Buy Sell

Overview

Share price change

24h

Current

Min

3.87

Max

4.03

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+264.02% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	345K 229M
Previous open	5.46
Previous close	3.97

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 kwi 2026, 23:26 UTC

Hot Stocks

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 kwi 2026, 20:41 UTC

Major Market Movers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 kwi 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 kwi 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 kwi 2026, 22:08 UTC

Earnings

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

16 kwi 2026, 20:49 UTC

Earnings

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 kwi 2026, 20:43 UTC

Earnings

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Netflix Says Engagement Quality Hits New High -- Market Talk

16 kwi 2026, 20:30 UTC

Hot Stocks

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 kwi 2026, 20:25 UTC

Earnings

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:23 UTC

Earnings

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 kwi 2026, 20:19 UTC

Earnings

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

264.02% upside

12 Months Forecast

Average 14.67 USD 264.02%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.